Revolution Medicines, Inc.

In July 2019, Revolution Medicines, Inc. announced the closing of a $100 million Series C equity financing. The Company has developed a proprietary drug discovery platform for synthesizing small molecule compounds to previously undruggable oncology targets.Proceeds will support continued advancement of the Company’s pipeline, which includes its lead compound, RMC-4630, a SHP2 inhibitor that is currently in a Phase 1/2 study for advanced solid tumors and additional compounds that address elusive targets within the RAS pathway such as KRASG12C(GTP) and other cancer targets. Furthermore, the Company plans to explore the combination of these compounds that have demonstrated promising results in preclinical studies.